

2 September 2024

Date of Annual General Meeting

In accordance with ASX Listing Rule 3.13.1, Ecofibre Limited (**Ecofibre, Company**) (ASX:EOF) advises that its Annual General Meeting (AGM) will be held at **11:00am** Australian Eastern Daylight Time (AEDT) on **Wednesday, 16 October 2024**. Details of the venue and the agenda will be provided in the formal Notice of Meeting.

Any nominations from persons wishing to be considered for election as a director at the AGM must be received at the Company's registered office at Level 12, 680 George Street, Sydney NSW 2000 no later than 5:00pm on Tuesday, 10 September 2024.

Investor Relations and Media, contact:

Level 12, 680 George Street, Sydney NSW 2000
Paul Edwards, investor-relations@ecofibre.com

About Ecofibre

Ecofibre owns a portfolio of high-quality advanced manufacturing and technology businesses in the United States and Australia.

We operate three vertically integrated businesses focused on sustainable polymers and natural materials, natural health care, and hemp seed genetics. In addition, we own a majority interest in a life sciences business that is developing treatments for malignant and non-malignant gynecological diseases.

Ecofibre Advanced Technologies (formerly known as Hemp Black) is an advanced manufacturing business with specialist capabilities in performance yarn extrusion and polymer compounding, sustainable materials and bioplastics.

Ananda Health is a leading US manufacturer of cannabinoid based health products for human and pet consumption. Our focus is on providing high-quality, research-backed products in Australia and the USA, targeting conditions including sleep, pain, anxiety, endometriosis, and other gynecological diseases. See anadaprofessional.com and anandahemp.com.au.

Ecofibre Genetics owns one of the world's largest collections of hemp seed genetics, and is a leading supplier of seed genetics to the hemp fibre and grain industry in the US and Australia.

EOF Bio Inc. is a majority owned, US-based clinical-stage biotechnology company focused on a new generation of patient-centered cannabinoid-based drugs that improve health outcomes and enhance quality of life, starting with women's health and endometriosis. Spun out of Ecofibre. In July 2023 it is focused on commercialising an expanding estate of issued patents.

Authorisation

This document is authorised to be given to the Australian Securities Exchange (ASX) by the Board of the Company.